PharmaShots Weekly Snapshots (March 18 – March 22, 2024)

Share this

PharmaShots Weekly Snapshots (March 18 – March 22, 2024)

This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:

Cybin Reports Initiation of the P-II Clinical Evaluation of CYB004 for the Treatment of Generalized Anxiety Disorder

Read More: Cybin                                                                                                                              

GSK Features Results from the P-III (RUBY) Study of Jemperli to Treat Endometrial Cancer at Society of Gynecologic Oncology 2024

Read More: GSK                                                                                                                              

Asieris Highlights the P-III Study Data of APL-1702 for Treating Cervical High-Grade Squamous Intraepithelial Lesions at the 2024 EUROGIN Congress and SGO Annual Meeting

Read More: Asieris Pharmaceuticals                                                                                             

AstraZeneca Features the P-III (DUO-E) Study Results Evaluating Imfinzi for the Treatment of Endometrial Cancer at SGO 2024

Read More: AstraZeneca                                                                                                  

Innovent Highlights the P-II Study Results of IBI302 to Treat Neovascular Age-related Macular Degeneration (nAMD)

Read More: Innovent                                                                                                                              

Bayer Reveals the P-III (OASIS 3) Trial Results of Elinzanetant to Treat Vasomotor Symptoms in Postmenopausal Women

Read More: Bayer                                                                                                                              

Jasper Therapeutics Doses First Patient with Briquilimab in the P-Ib/IIa Study to Treat Chronic Inducible Urticaria

Read More: Jasper Therapeutics                                                                      

Merck Features Data from a Series of P-III Trials Assessing V116 Vaccine for Pneumococcal Diseases at ISPPD-13 2024

Read More: Merck                                                                                                                              

Merck Reports P-III (KEYLYNK-006) Study Results of Keytruda to Treat Metastatic Non-squamous NSCLC

Read More: Merck                                                                                                                              

Molecure Doses First Patient with OATD-01 in the P-II (KITE) Trial for Treating Pulmonary Sarcoidosis Across the UK 

Read More: Molecure                                                                                                                              

AstraZeneca Reports Results from the P-III (FLAURA2) Trial of Tagrisso Plus Chemotherapy to Treat Advanced Lung Cancer

Read More: AstraZeneca                                                                      

The US FDA Grants Approval to Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for Treating NASH with Liver Fibrosis

Read More: Madrigal Pharmaceuticals                                                                                     

The US FDA’s ODAC Recommends Johnson & Johnson’s Carvykti for the Treatment of Relapsed/Refractory Multiple Myeloma

Read More: Johnson & Johnson                                                                                                             

The US FDA Grants Approval to Orchard Therapeutics’ Lenmeldy for Treating Metachromatic Leukodystrophy

Read More: Orchard Therapeutics                                                                                                          

Health Canada Accepts for Review Biogen Canada’s New Drug Submission of Tofersen for the Treatment of Amyotrophic Lateral Sclerosis

Read More: Biogen              

The EC Grants Approval to BMS’ Abecma for the Treatment of Relapsed/Refractory Multiple Myeloma

Read More: BMS                                       

The US FDA Grants Orphan Drug Designation to Cabaletta Bio’s CABA-201 for Treating Systemic Sclerosis

Read More: Cabaletta Bio                                                                                             

The US FDA Approves Italfarmaco’s Duvyzat (givinostat) for Treating Duchenne Muscular Dystrophy

Read More: Italfarmaco                                                                                        

Fennec Pharmaceuticals and Norgine Join Forces to Commercialize Pedmarqsi in the EU, Australia and New Zealand

Read More: Fennec Pharmaceuticals & Norgine                                                                                

Sanyou Bio Partners with BioGeometry to Develop AIGC Driven Antibody Drug Discovery Platform 

Read More: Sanyou Bio & BioGeometry                                                                                         

Bio-Thera Solutions and SteinCares Join Forces for Marketing Biosimilars Across LATAM

Read More: Bio-Thera Solutions & SteinCares                                                                                   

Evommune Expands its Partnership with Maruho for the Development and Commercialization of EVO756 in Greater China and Asian Countries

Read More: Evommune & Maruho                                                                                                 

Bayer and Thermo Fisher Scientific Collaborate on NGS-Based Companion Diagnostic Assays (CDx)

Read More: Bayer & Thermo Fisher Scientific                                                                                 

Kazia Therapeutics Partners with Sovargen to Develop Paxalisib for the Treatment of Intractable Seizures in Rare CNS Diseases

Read More: Kazia Therapeutics & Sovargen                                                                                   

Relief Therapeutics Collaborates with Eton Pharmaceuticals to Commercialize Golike Products for Phenylketonuria

Read More: Relief Therapeutics & Eton Pharmaceuticals                                                               

The US FDA Grants Breakthrough Device Designation to Vicore’s Almee for Pulmonary Fibrosis

Read More: Vicore                               

The US FDA Grants 510(k) Clearance to inHEART’s AI-Based Software Module for Creating 3D Cardiac Models

Read More: inHEART                                 

Onymos and Vapotherm Collaborate for Developing an End-to-End Internet of Medical Things Solution (IoMT)

Read More: Onymos & Vapotherm                                                                                                  

TELA Bio Launches its LIQUIFIX FIX8 and LIQUIFIX Precision Devices for Internal Use in Hernia Surgery Across the US

Read More: TELA Bio                                                  

For an Aggregate of ~2.4B, AstraZeneca to Acquire Fusion Pharmaceuticals for the Development of Radioconjugates

Read More: AstraZeneca & Fusion Pharmaceuticals         

Related Post:- PharmaShots Weekly Snapshots (March 11 – March 15, 2024)                                                                                           

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions